We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Scientific Data Highlights Pivotal Role of Monogram's Molecular Diagnostics in Development of New HIV Treatments

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Monogram Biosciences, Inc. has announced 20 presentations related to its portfolio of HIV diagnostic assays at the 14th Annual Conference on Retroviruses and Opportunistic Infections (CROI).

Data presented at the conference demonstrate the pivotal role played by Monogram's HIV assays in delivering personalized patient care by providing critical information that facilitates physician management of patient treatment regimens and assists pharmaceutical companies in their ability to develop new drugs and new drug classes.

"Important phase III data was presented at CROI by Pfizer on their investigational CCR5 antagonist and by Merck on their investigational integrase inhibitor," said William Young, CEO of Monogram.

"The advent of two new classes of HIV drugs is potentially the most significant development for HIV patients in a decade and I am proud that Monogram's assays are playing a critical enabling role in the development of these drugs and in determining their clinical utility," Young added.

Monogram's assays were used to optimize background therapy in the clinical trials of both new drugs and in the case of maraviroc, Pfizer's CCR5 antagonist, Monogram's Trofile Assay was used for patient selection and enabled the positive results reported by Pfizer at CROI.

"Pfizer's phase III results indicate that patients, when properly selected with our assay, responded to maraviroc, and experienced a significant reduction in viral load," continued Young. "Data previously reported by Pfizer indicate that patients who are identified with our Trofile Assay as not being appropriate for the drug, in fact, did not respond to maraviroc."

Maraviroc has been granted accelerated review by U.S., Canadian and European regulators, and if approved, would be the first new oral class of HIV medicines in more than a decade.

"The breadth and depth of the scientific data presented at CROI by Monogram scientists and collaborators demonstrate the position of strong scientific leadership that is Monogram's hallmark," said Christos Petropoulos, Chief Scientific Officer at Monogram.